SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: billkirn who wrote (5728)12/3/1998 8:01:00 PM
From: Henry Niman  Read Replies (1) | Respond to of 6136
 
Today Everen came out with an OUTPERFORM rating on VRTX and discussed
Agenerase approval. Details linked to the anti-HIV table on the New
Therapeutics page at biocognizance.com (if your ISP hasn't refreshed yet, the site can also be accessed at 206.86.188.121 ).



To: billkirn who wrote (5728)12/4/1998 4:33:00 PM
From: Izzy  Read Replies (1) | Respond to of 6136
 
Bill, if you update your web site you could use your note of 12-7-97 again this year: "should get back to the mid to upper 40's..." but you can now project a price range into the 50s short term, if you agree. Of course I would expect a price adjustment for "AGPH General" when the oncology division stock begins trading.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News